Please ensure Javascript is enabled for purposes of website accessibility

Twist Biosciences and Agilent Settle Dispute, Avoid Costly Trial

By Todd Campbell - Feb 7, 2020 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Twist will pay Agilent $22.5 million and receive a license to aspects of its technology.

A trial to resolve Agilent's (A 0.55%) dispute with biotech company Twist Biosciences (TWST 6.06%) won't begin on Feb. 24 after all. Instead, Twist is paying $22.5 million to settle -- without admission of wrongdoing -- litigation alleging breach of contract, breach of duty of loyalty, and alleged misappropriation of trade secrets by Twist's management, including CEO and co-founder Emily Leproust, a former Agilent employee.

Specifically, Agilent alleged Leproust used confidential information "relating to Agilent's oligonucleotide synthesis technology to develop Twist's technology and identify personnel to hire from Agilent," according to Twist's annual 10-K filing with the Securities and Exchange Commission.

Furthermore, Agilent alleged Leproust "withheld strategic business and technological plans from Agilent and diverted those plans to Twist instead," and "violated her contractual obligations under her employment agreement with Agilent, including by failing to disclose the aforementioned plans and by soliciting one or more Agilent employees to terminate their employment within two years of her resignation." 

An outstretched hand holding stacks of $100 bills.

IMAGE SOURCE: GETTY IMAGES.

As per the settlement, Agilent will pocket $22.5 million from Twist in exchange for a license to aspects of Agilent's oligo-synthesis technology. 

"This settlement vindicates Agilent's deep commitment to protecting our intellectual property," said Simone Schiller, associate vice president and managing counsel for global litigation at Agilent. "Agilent is in the business of innovation and driving technology forward the right way is central to what we do. From the outset, our goal has been to protect our proprietary technology and the hard work of the many scientists and engineers who built it. This settlement accomplishes that."

Speaking on  Twist's earnings conference call Friday, Leproust had this to say about the settlement:

"The settlement agreement contains no admission of liability or wrongdoing because there were none. Agilent launched an all-out legal assault on Twist, and in the end, we not only survived but we thrived through the attack. We were prepared to take this case to trial. However, we have chosen to settle this litigation to remove the uncertainty and exceptional legal fees associated with the jury trial."

With the costly overhang and distraction gone, Twist's focus will be firmly on creating products that help researchers deliver on the promise associated with synthetic biology and gene sequencing, a $2.3 billion market. Last quarter, its revenue increased 49.3% year over year to $17.2 million, including $12.3 million in synthetic biology sales. For fiscal 2020, Twist forecasts revenue exceeding $80 million.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Twist Bioscience Corporation Stock Quote
Twist Bioscience Corporation
TWST
$37.08 (6.06%) $2.12
Agilent Technologies, Inc. Stock Quote
Agilent Technologies, Inc.
A
$119.21 (0.55%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.